Brighton Jones’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$496K Buy
+2,575
New +$278K 0.01% 815
2023
Q2
– Sell
-2,042
Closed -$314K – 554
2023
Q1
$314K Buy
2,042
+35
+2% +$5.77K 0.02% 367
2022
Q4
$361K Sell
2,007
-41
-2% -$6.7K 0.02% 299
2022
Q3
$242K Buy
2,048
+425
+26% +$64.5K 0.01% 374
2022
Q2
$232K Sell
1,623
-233
-13% -$33.3K 0.01% 390
2022
Q1
$320K Buy
1,856
+102
+6% +$17.2K 0.01% 353
2021
Q4
$446K Buy
1,754
+29
+2% +$8.48K 0.02% 300
2021
Q3
$664K Sell
1,725
-60
-3% -$22.1K 0.03% 215
2021
Q2
$419K Buy
1,785
+73
+4% +$13K 0.02% 284
2021
Q1
$224K Sell
1,712
-1,341
-44% -$194K 0.01% 376
2020
Q4
$319K Buy
+3,053
New +$309K 0.02% 281
2020
Q3
– Sell
-6,475
Closed -$416K – 343
2020
Q2
$416K Buy
+6,475
New +$355K 0.03% 186

Other funds holding MRNA

Brighton Jones's MRNA Position: Q3 2026 in Review

Brighton Jones opened a new position in Moderna (MRNA) in Q3 2026: 2,575 shares worth $496K. The stake represents 0.01% of the portfolio and ranks #815 among its holdings. This is a return to the name: Brighton Jones previously reported a position in MRNA as recently as Q1 2023.

Brighton Jones first reported a position in MRNA in Q2 2020 and has held it in 12 quarters since. The position peaked at $664K in Q3 2021. 1,028 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Brighton Jones held 2,575 shares of Moderna worth $496K as of Q3 2026.
  • Moderna was a new Brighton Jones position in Q3 2026.
  • Moderna made up 0.01% of Brighton Jones's portfolio in Q3 2026, its #815 holding.
  • Brighton Jones first reported a position in Moderna in Q2 2020 and has held it in 12 quarters since.
  • Brighton Jones's Moderna position peaked at $664K in Q3 2021.
  • 1,028 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.